Novel Antibodies Targeting IL-2Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg. IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay between IL-2 and IL-2R and various immune cells and their dual roles in shaping the immune response presents a complex landscape for clinical exploitation. The Need There is a pressing need for effective treatment options for conditions associated with IL-2 signaling, such as cancer and autoimmune disorders. Current treatments often fall short in providing adequate clinical response and immune modulation. IL-2 antibodies offer a promising solution by targeting specific pathways involved in disease progression and immune dysfunction. The Technology Researchers at The Ohio State University have developed novel IL-2 antibodies designed to bind human IL-2, modulating its signaling pathways and improving clinical outcomes. These antibodies have differential effects on IL-2 binding to its receptors, offering targeted therapy options. With high affinity and specificity, these novel IL-2 antibodies inhibit IL-2 signaling through various receptor chains, including IL-2 Rα and IL-2 Rβg. Commercial Applications
Benefits/Advantages
Issued US Patent |
Tech IDT2024-270 CollegeLicensing ManagerWillson, Christopher Inventors(None) Categories |